Cargando…
Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser(280) by Hallucinogenic versus Nonhallucinogenic Agonists
The serotonin 5-HT(2A) receptor is a primary target of psychedelic hallucinogens such as lysergic acid diethylamine, mescaline, and psilocybin, which reproduce some of the core symptoms of schizophrenia. An incompletely resolved paradox is that only some 5-HT(2A) receptor agonists exhibit hallucinog...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society for Biochemistry and Molecular Biology
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014284/ https://www.ncbi.nlm.nih.gov/pubmed/24637012 http://dx.doi.org/10.1074/mcp.M113.036558 |
_version_ | 1782315152440295424 |
---|---|
author | Karaki, Samah Becamel, Carine Murat, Samy Mannoury la Cour, Clotilde Millan, Mark J. Prézeau, Laurent Bockaert, Joël Marin, Philippe Vandermoere, Franck |
author_facet | Karaki, Samah Becamel, Carine Murat, Samy Mannoury la Cour, Clotilde Millan, Mark J. Prézeau, Laurent Bockaert, Joël Marin, Philippe Vandermoere, Franck |
author_sort | Karaki, Samah |
collection | PubMed |
description | The serotonin 5-HT(2A) receptor is a primary target of psychedelic hallucinogens such as lysergic acid diethylamine, mescaline, and psilocybin, which reproduce some of the core symptoms of schizophrenia. An incompletely resolved paradox is that only some 5-HT(2A) receptor agonists exhibit hallucinogenic activity, whereas structurally related agonists with comparable affinity and activity lack such a psychoactive activity. Using a strategy combining stable isotope labeling by amino acids in cell culture with enrichment in phosphorylated peptides by means of hydrophilic interaction liquid chromatography followed by immobilized metal affinity chromatography, we compared the phosphoproteome in HEK-293 cells transiently expressing the 5-HT(2A) receptor and exposed to either vehicle or the synthetic hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) or the nonhallucinogenic 5-HT(2A) agonist lisuride. Among the 5995 identified phosphorylated peptides, 16 sites were differentially phosphorylated upon exposure of cells to DOI versus lisuride. These include a serine (Ser(280)) located in the third intracellular loop of the 5-HT(2A) receptor, a region important for its desensitization. The specific phosphorylation of Ser(280) by hallucinogens was further validated by quantitative mass spectrometry analysis of immunopurified receptor digests and by Western blotting using a phosphosite specific antibody. The administration of DOI, but not of lisuride, to mice, enhanced the phosphorylation of 5-HT(2A) receptors at Ser(280) in the prefrontal cortex. Moreover, hallucinogens induced a less pronounced desensitization of receptor-operated signaling in HEK-293 cells and neurons than did nonhallucinogenic agonists. The mutation of Ser(280) to aspartic acid (to mimic phosphorylation) reduced receptor desensitization by nonhallucinogenic agonists, whereas its mutation to alanine increased the ability of hallucinogens to desensitize the receptor. This study reveals a biased phosphorylation of the 5-HT(2A) receptor in response to hallucinogenic versus nonhallucinogenic agonists, which underlies their distinct capacity to desensitize the receptor. |
format | Online Article Text |
id | pubmed-4014284 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | The American Society for Biochemistry and Molecular Biology |
record_format | MEDLINE/PubMed |
spelling | pubmed-40142842014-06-20 Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser(280) by Hallucinogenic versus Nonhallucinogenic Agonists Karaki, Samah Becamel, Carine Murat, Samy Mannoury la Cour, Clotilde Millan, Mark J. Prézeau, Laurent Bockaert, Joël Marin, Philippe Vandermoere, Franck Mol Cell Proteomics Research The serotonin 5-HT(2A) receptor is a primary target of psychedelic hallucinogens such as lysergic acid diethylamine, mescaline, and psilocybin, which reproduce some of the core symptoms of schizophrenia. An incompletely resolved paradox is that only some 5-HT(2A) receptor agonists exhibit hallucinogenic activity, whereas structurally related agonists with comparable affinity and activity lack such a psychoactive activity. Using a strategy combining stable isotope labeling by amino acids in cell culture with enrichment in phosphorylated peptides by means of hydrophilic interaction liquid chromatography followed by immobilized metal affinity chromatography, we compared the phosphoproteome in HEK-293 cells transiently expressing the 5-HT(2A) receptor and exposed to either vehicle or the synthetic hallucinogen 1-[2,5-dimethoxy-4-iodophenyl]-2-aminopropane (DOI) or the nonhallucinogenic 5-HT(2A) agonist lisuride. Among the 5995 identified phosphorylated peptides, 16 sites were differentially phosphorylated upon exposure of cells to DOI versus lisuride. These include a serine (Ser(280)) located in the third intracellular loop of the 5-HT(2A) receptor, a region important for its desensitization. The specific phosphorylation of Ser(280) by hallucinogens was further validated by quantitative mass spectrometry analysis of immunopurified receptor digests and by Western blotting using a phosphosite specific antibody. The administration of DOI, but not of lisuride, to mice, enhanced the phosphorylation of 5-HT(2A) receptors at Ser(280) in the prefrontal cortex. Moreover, hallucinogens induced a less pronounced desensitization of receptor-operated signaling in HEK-293 cells and neurons than did nonhallucinogenic agonists. The mutation of Ser(280) to aspartic acid (to mimic phosphorylation) reduced receptor desensitization by nonhallucinogenic agonists, whereas its mutation to alanine increased the ability of hallucinogens to desensitize the receptor. This study reveals a biased phosphorylation of the 5-HT(2A) receptor in response to hallucinogenic versus nonhallucinogenic agonists, which underlies their distinct capacity to desensitize the receptor. The American Society for Biochemistry and Molecular Biology 2014-05 2014-03-17 /pmc/articles/PMC4014284/ /pubmed/24637012 http://dx.doi.org/10.1074/mcp.M113.036558 Text en © 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Author's Choice—Final version full access. |
spellingShingle | Research Karaki, Samah Becamel, Carine Murat, Samy Mannoury la Cour, Clotilde Millan, Mark J. Prézeau, Laurent Bockaert, Joël Marin, Philippe Vandermoere, Franck Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser(280) by Hallucinogenic versus Nonhallucinogenic Agonists |
title | Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser(280) by Hallucinogenic versus Nonhallucinogenic Agonists |
title_full | Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser(280) by Hallucinogenic versus Nonhallucinogenic Agonists |
title_fullStr | Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser(280) by Hallucinogenic versus Nonhallucinogenic Agonists |
title_full_unstemmed | Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser(280) by Hallucinogenic versus Nonhallucinogenic Agonists |
title_short | Quantitative Phosphoproteomics Unravels Biased Phosphorylation of Serotonin 2A Receptor at Ser(280) by Hallucinogenic versus Nonhallucinogenic Agonists |
title_sort | quantitative phosphoproteomics unravels biased phosphorylation of serotonin 2a receptor at ser(280) by hallucinogenic versus nonhallucinogenic agonists |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014284/ https://www.ncbi.nlm.nih.gov/pubmed/24637012 http://dx.doi.org/10.1074/mcp.M113.036558 |
work_keys_str_mv | AT karakisamah quantitativephosphoproteomicsunravelsbiasedphosphorylationofserotonin2areceptoratser280byhallucinogenicversusnonhallucinogenicagonists AT becamelcarine quantitativephosphoproteomicsunravelsbiasedphosphorylationofserotonin2areceptoratser280byhallucinogenicversusnonhallucinogenicagonists AT muratsamy quantitativephosphoproteomicsunravelsbiasedphosphorylationofserotonin2areceptoratser280byhallucinogenicversusnonhallucinogenicagonists AT mannourylacourclotilde quantitativephosphoproteomicsunravelsbiasedphosphorylationofserotonin2areceptoratser280byhallucinogenicversusnonhallucinogenicagonists AT millanmarkj quantitativephosphoproteomicsunravelsbiasedphosphorylationofserotonin2areceptoratser280byhallucinogenicversusnonhallucinogenicagonists AT prezeaulaurent quantitativephosphoproteomicsunravelsbiasedphosphorylationofserotonin2areceptoratser280byhallucinogenicversusnonhallucinogenicagonists AT bockaertjoel quantitativephosphoproteomicsunravelsbiasedphosphorylationofserotonin2areceptoratser280byhallucinogenicversusnonhallucinogenicagonists AT marinphilippe quantitativephosphoproteomicsunravelsbiasedphosphorylationofserotonin2areceptoratser280byhallucinogenicversusnonhallucinogenicagonists AT vandermoerefranck quantitativephosphoproteomicsunravelsbiasedphosphorylationofserotonin2areceptoratser280byhallucinogenicversusnonhallucinogenicagonists |